Medtronic shares have climbed over the past three years, helped by solid recent gains. That rise raises a simple question for you as an investor: Is the current US$101.59 price broadly in line with what the company’s cash flows can support over time, or has sentiment moved ahead of the underlying numbers?
- The stock has returned 54.4% over the past three years, which puts real weight on whether the cash generation story justifies that kind of performance.
- Fresh data on the Symplicity Spyral renal denervation system and new FDA labeling may support expectations for future treatment adoption, which in turn can influence how investors think about Medtronic’s long term cash flow profile.
- What if you looked at Medtronic through its earnings instead? See why Medtronic's 23.8x P/E tells a different valuation story.
The stock’s next move may depend on whether that recent share price level lines up with what a Discounted Cash Flow (DCF) view of Medtronic’s cash flows suggests the business is worth.
If you want a reference point for Medtronic’s recent gains and cash flow story, compare it with other 36 healthcare AI stocks
Does Medtronic Look Fairly Valued on Cash Flow?
The Discounted Cash Flow (DCF) model here projects what Medtronic’s future excess cash might be worth in today’s money. Over the last twelve months the group produced free cash flow of about $6.1b, and the DCF framework assumes those cash flows keep growing rather than shrinking over the coming decade as the business leans on its device portfolio.
Analyst projections feeding the model point to free cash flow remaining in the multi billion dollar range through the early 2030s. This is consistent with a mature, cash generative healthcare company rather than a high risk turnaround story. Because the Discounted Cash Flow (DCF) output comes out broadly in line with the current $101.59 share price, the recent FDA label update for the Symplicity Spyral renal denervation system helps explain why investors appear comfortable paying roughly what the projected cash flows suggest Medtronic is worth. Find out what Medtronic could be worth using our Discounted Cash Flow (DCF) estimate.
The Medtronic Narrative: What Would Justify Today's Price?
Narratives for Medtronic pick up where the valuation puzzle leaves off. They spell out which paths for future growth, profitability and earnings would need to play out for the stock to be worth materially more or less than the current price, and they sit on Simply Wall St's Community page so you can see those assumptions set out in plain language. Where a single ratio or DCF output gives one number, these narratives describe the future that number relies on so you can watch how reality compares over time.
Bullish and cautious takes on Medtronic hinge on how durable its product mix and cash generation look from here.
Bull case: roughly fairly valued
The analyst consensus Narrative on Simply Wall St frames the optimistic view around Medtronic’s higher growth cardiovascular and robotics platforms.
"Increased annual spend on R&D and acquisitions to an estimated US$5b to US$6b, including investments in renal denervation, pelvic neuromodulation, structural heart and neurovascular therapies…"
Discover why this Narrative puts Medtronic at roughly fairly valued.
Bear case: 12% overvalued
According to Silvester, an investor in the Simply Wall St Community, current Medtronic enthusiasm may already bake in a lot of that progress.
"Although analysts are showing some caution and issuing various price targets, I found the timing of entry favorable…"
Explore why this Narrative puts Medtronic at 12% overvalued.
Before acting on Medtronic's valuation, there is one more piece to weigh
Cash flows and products only tell part of the Medtronic story, because the people setting priorities and how they are rewarded can tilt risk and return in very different directions. See who runs Medtronic and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com